FIGURE 2.

Least squares mean change from baseline in FEV₁ (L) during the 24‐wk treatment period in the phase 2b study in patients with uncontrolled, persistent asthma and 52‐wk treatment period in the phase 3 QUEST study in patients with uncontrolled, moderate‐to‐severe asthma on high‐dose ICS at baseline and further stratified by baseline eosinophil and FeNO levels. ^†In the phase 2b study, the same amount of placebo was given regardless of dupilumab dose (not volume‐matched as in the phase 3 QUEST study). ***P < .001, **P < .01, *P < .05 vs placebo. FeNO, fractional exhaled nitric oxide; FEV₁, forced expiratory volume in 1 s; ICS, inhaled corticosteroids; LS, least squares; q2w, every 2 wk; SE, standard error